3126 Efficacy and Safety of Sublingual Immunotherapy in House Dust Mite Sensitized Children with Allergic Rhinitis.

Friday, 16 October 2015
Hall D1 Foyer (Floor 3) (Coex Convention Center)

Yang Park, MD, PhD , Department of Pediatrics, Wonkwang University Sanbon Medical Center, Kunpo, South Korea

Background : This study investigated the efficacy and safety of sublingual immunotherapy (SLIT) with house dust mite in house dust mite sensitized children with allergic rhinitis.

Method : 14 children who were sensitized to house dust mites treated with SLIT enrolled between August 2013 and July 2014. Nasal symptoms (rhinorrhea, sneezing, nasal obstruction, nasal itching, sleep disturbance), antiallergic medications use and presence of adverse events were assessed at 1 month, 2 month visit and thereafter every 3 months visits.

Results : The symtoms of allergic rhinitis started to improve after 1 month of SLIT and significantly improved after 12 months of SLIT (P<0.05). The antiallergic medications use decreased significantly with time (P<0.05). The incidence of adverse events was 21.4 % and most occured within the first month of SLIT and disappeared with time. There were no severe adverse events.

Conclusion : SLIT for house dust mite is effective and safe in house dust mite sensitized children with allergic rhinitis.